- Home
- » Tags
- » Cloperastine
Top View
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- Identification of Endogenous Function and Substrate-Dependent Interactions of Organic Cation Transporter 1
- Molecular Modeling of Histamine Receptors—Recent Advances in Drug Discovery
- Table S1. Characteristics of Repurposed Drugs/Compounds for Control of Fungal Pathogens. 1 Compounds Original Functions Target F
- View U.S. Patent No. 10124008 in PDF
- Wo 2009/104080 A2
- General Information
- (10) Patent No.: US 8,512,759 B1 Mcmahen Et Al
- A Full Cycle Anti-Viral Drug Screen Identifies a Clinical Compound
- Who Drug Information
- 1554 Cough Suppressants Expectorants Mucolytics and Nasal Decongestants Chronic Obstructive Pulmonary Disease
- Cloperastine Inhibits Esophageal Squamous Cell Carcinoma Proliferation in Vivo and in Vitro by Suppressing Mitochondrial Oxidative Phosphorylation
- Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
- United States Patent (10) Patent No.: US 8,062,667 B2 Mehta Et Al
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- A Case Control-Study of Cloperastine Treatment in Covid-19. Potential Drug, Clinical Observation and Common Sense
- Antitussive Drugs—Past, Present, and Future
- Targeting Quorum Sensing
- 19 1 2005.Pdf (286.3Kb)
- Ligand P-Gp Inhibition
- ICD-10-CM Table of Drugs 2019
- L:\0900\0900PHARMAPPX .Wpd
- Update on Functional Inhibitors of Acid Sphingomyelinase (Fiasmas) in SARS-Cov-2 Infection
- Reflections on the Special Experiment in General Medicine of the Non-Specific Antiviral Drug, and Authorized As Antitussive, Cloperastine
- Stereoselective Reduction of Prochiral Ketones by Plant and Microbial Biocatalysts
- (12) United States Patent (10) Patent No.: US 8,729,070 B2 Glozman (45) Date of Patent: May 20, 2014
- Supporting Information
- Who Drug Information
- Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving
- Butropium Bromide 1 Butropium Bromide 2 Cadralazine
- Ultraviolet-Visible Reference Spectra
- 1 Lysosomotropic Active Compounds— Hidden Protection
- Clinical Drug Investigation 22
- Development and Validation of RP-HPLC Method for Simultaneous Estimation of Levocloperastine Fendizoate and Chlorpheniramine Maleate in Their Combined Dosage Form
- Designing, Docking and Molecular Dynamics Simulation Studies Of
- Pharmacological and Clinical Overview of Cloperastine in Treatment of Cough